IPG-1094
- Generic Name
- IPG-1094
Phase I/II Study of IPG1094 in Advanced Solid Tumors Patients
- First Posted Date
- 2024-01-18
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Nanjing Immunophage Biotech Co., Ltd
- Target Recruit Count
- 60
- Registration Number
- NCT06212076
- Locations
- 🇨🇳
Shanghai GoBroad Cancer Hospital China Pharmaceutical University, Shanghai, China
🇨🇳Shanghai General Hospital, Shanghai, Shanghai, China
Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors
- First Posted Date
- 2021-12-02
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- Nanjing Immunophage Biotech Co., Ltd
- Target Recruit Count
- 196
- Registration Number
- NCT05142592
- Locations
- 🇺🇸
Providence Portland Medical Center, Portland, Oregon, United States
🇨🇳The First Affiliated Hospital Nanchang Univeristy, Nanchang, Jiangxi, China
🇨🇳Shandong Cancer Hospital, Jinan, Shangdong, China
Study of IPG1094 in Healthy Participants
- First Posted Date
- 2021-11-08
- Last Posted Date
- 2021-11-08
- Lead Sponsor
- Nanjing Immunophage Biotech Co., Ltd
- Target Recruit Count
- 46
- Registration Number
- NCT05112159
- Locations
- 🇦🇺
Scientia Clinical Research Ltd, Randwick, New South Wales, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath